RxDoctor Payments Data

James Lyons, MD

Advanced Heart Failure and Transplant Cardiology · Poughkeepsie, NYNPI 1053306183

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,950 of the $10,264 with a category attached, or 77.5%. Novartis accounts for 81.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $8,948 and has fallen 95.5% since, to $399 in 2025.

$10,264in general payments, 2019–2025

Across 82 payments — averaging $125.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$8K
  • Abbott$1K
  • Amgen$126
  • Boehringer Ingelheim$88
  • Medtronic$72
  • Impulse Dynamics (USA) Inc.$72
  • plus $328 from 9 others
$943,706in research payments, 2019–2025

Across 82 payments — averaging $11,509 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$517K
  • Medtronic$178K
  • Abbott$81K
  • AstraZeneca$66K
  • Procyrion, Inc.$43K
  • Amgen$30K
  • plus $30K from 2 others

What the payments were for

  • Speaking & faculty fees$7,95077%
  • Food & beverage$2,31423%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,264 in reported general payments places this provider in the 65th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

See all advanced heart failure and transplant cardiology providers in New York

Medicare billing

Part B allowed, 2024
$283,148
Medicare patients
2,194
Services billed
5,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban329$461,311
EntrestoSacubitril/Valsartan229$345,783
FarxigaDapagliflozin Propanediol228$246,533
XareltoRivaroxaban38$59,127
JardianceEmpagliflozin40$39,009
Repatha SureclickEvolocumab25$21,735
BrilintaTicagrelor13$16,771
Ranolazine ErRanolazine70$8,371
Metoprolol Succinate339$6,447
Atorvastatin Calcium417$4,466
Torsemide88$3,177
Rosuvastatin Calcium107$2,377
Carvedilol282$2,226
Dofetilide14$2,211
Bumetanide32$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$461,311329 claims
NovartisEntresto$8,371$345,783229 claims
AstraZenecaFarxiga, Brilinta$25$263,304241 claims
Johnson & JohnsonXarelto$26$59,12738 claims
Boehringer IngelheimJardiance$88$39,00940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 106 advanced heart failure and transplant cardiology providers in New York.

Other advanced heart failure and transplant cardiology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →